Biopharmaceutical Analysis

The BioProfile FAST CDV is a fully automated viable cell density and viability analyzer.

Pfizer and Gero have partnered to discover potential therapeutic targets for fibrotic diseases using machine learning technology.

The collaboration between AbbVie and Anima Biotech will combine Anima's mRNA Lightning technology platform with AbbVie's extensive expertise in oncology and immunology.

Advanced LC technologies can streamline the review process for LC equipment maintenance.

Biologic drug development requires relevant bioassays to measure and help predict cellular response.

Webinar Date/Time: Monday, March 20th, 2023 at 11am EDT|8am PDT|3pm GMT|4pm CET

The launch of Discovery Life Sciences’ new Proteomic Services Division offers a single source for large-scale population studies, biobank characterization, and multi-omic biomarker analysis.

Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.

PictorLabs, a digital pathology company developing an AI-powered virtual staining platform, formally announced its launch at the start of December.

The design of viral clearance studies must keep pace with the quickly evolving biologic drugs industry.

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

Webinar Date/Time: Tue, Dec 6, 2022 11:00 AM EST

Webinar Date/Time: Wed, Dec 14, 2022 11:00 AM EST

Webinar Date/Time: Friday, December 9th, 2022 at 11am EST|8am PST|4pm GMT|5pm CET

A novel mathematical approach for fitting concentration-response curves is proposed that offers a more accurate estimation of potency data.

Webinar Date/Time: Thu, Dec 1, 2022 11:00 AM EST

Tuesday, November 15th 2022 Morning Session: 11am EST|8am PST|4pm GMT|5pm CET Afternoon Session: 2pm EST|11am PST|7pm GMT|8pm CET Analyzing oligos? Join us to learn about novel, automated, and integrated software to support the analysis of the CQAs of oligos using LC–HRAM MS. Purity and sequencing data will be presented for a multitude of oligos including antisense, aptamer, and long synthetic samples.

The collaboration will see Shimadzu and UMG develop new clinical laboratory methods using LC-MS for TDM analysis.

An orthogonal approach to lipid nanoparticle analysis is recommended to optimize drug development success.

Under this deal, Merck, known as MSD outside of the United States and Canada, will select Veeva products for industry-specific software and data.

A thorough knowledge of both the upstream and downstream processes is required to ensure effective removal of residual impurities in biopharmaceuticals.

Content is king in publishing, but interpretation is imperator.

Using a predictive modeling approach can help tighten up operator control over bioprocessing, which in turn can increase bioreactor output.

OGT has launched the SureSeq Myeloid Plus panel and OGT Universal NGS Complete Workflow.

Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.

Assessment of peripheral blood protein glycosylation has recently become scalable, providing a new domain for biomarker research.

PerkinElmer has unveiled a cell analysis solution to streamline cell and gene therapy research and manufacturing.

A combination of eye imaging techniques and adaptive optics has revealed key details of choroideremia.

The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.

Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.